Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas
Open Access
- 6 June 2008
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 19 (10) , 1774-1786
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) exhibits heterogeneous clinical features and a marked variable response to treatment. Patients and methods: We investigated the prognostic significance of the methylation status of DAPK, GSTP1, P14, P15, P16, P33, RB1, SHP1, CDH1, APC, BLU, VHL, TIMP3, and RASSF1A genes in 46 DLBCL specimens from Tunisian patients. Methylation status of each gene was correlated with clinicopathological parameters including the International Prognostic Index (IPI), the germinal center immunophenotype, and response to treatment and survival. Overall survival (OS) and disease-free survival (DFS) rates were calculated by the Kaplan–Meier method and differences were compared with the log-rank test. Results: Hypermethylation of SHP1 was associated with elevated lactate dehydrogenase level (P = 0.031). P16 and VHL were frequently hypermethylated in patients with high IPI scores (P = 0.006 and 0.004) and a performance status of two or more (P = 0.007 and 0.047). In addition, hypermethylation of P16 was significantly associated with advanced clinical stages and B symptoms (P = 0.041 and 0.012). Interestingly, hypermethylation of DAPK was significantly correlated with resistance to treatment (P = 0.023). With regard to survival rates, promoter hypermethylation of DAPK, P16, and VHL were significantly associated with shortened OS (P = 0.003, 0.001, and 0.017, respectively) and DFS (P = 0.006, 0.003, and 0.046, respectively). In multivariate analysis, hypermethylation of DAPK remains an independent prognostic factor in predicting shortened OS (P = 0.001) and DFS (P = 0.024), as well as the IPI and the germinal center status. Conclusions: This study demonstrates that DLBCLs with hypermethylated P16, VHL, DAPK, and SHP1 commonly show a biologically aggressive phenotype and worse prognosis. Interestingly, hypermethylation of DAPK was found to be an independent prognostic factor that may be used in conjunction with the conventional prognostic factors such as the IPI and the germinal center status.Keywords
Funding Information
- Ministry of Higher Education, Scientific Research, and Technology
This publication has 57 references indexed in Scilit:
- Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and P53 accumulationLaboratory Investigation, 2008
- Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesotheliomaLung Cancer, 2006
- Epigenetic and genetic alterations of p33 ING1b in ovarian cancerCarcinogenesis, 2005
- Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemiaBlood, 2004
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignanciesBlood, 2004
- Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancersOncogene, 2003
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Alterations of CDKN2 (MTS1/p16INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancersExperimental & Molecular Medicine, 1998
- Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibitionNature, 1995
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993